National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Aflibercept for the treatment of metastatic colorectal cancer in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy is indicated in adults with metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen.

Rapid Review

Commenced Completed Outcome
21/03/2013 10/04/2013 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
 04/10/2013  12/02/2014  Reimbursement Recommended

The NCPE believe that when compared to alternative biological agents aflibercept may be considered cost saving.

Aflibercept summary